BRD4 and cancer: Several BRD4 inhibitors, known as Bromo‐ and Extra‐Terminal domain (BET) inhibitors (BETi), have been tested in multiple cancer models, and 30 clinical trials are currently ongoing to evaluate their anticancer efficacy (Shorstova et al, 2021).